Introduction
Atrial fibrillation is the commonest sustained cardiac rhythm abnormality, leading to substantial mortality and morbidity from stroke, thromboembolism and heart failure. Whilst the benefits of antithrombotic therapy in preventing stroke in atrial fibrillation are increasingly recognised, further developments in thromboprophylaxis are needed, especially since warfarin confers the inconvenience of regular anticoagulation monitoring and the benefits of aspirin are inconsistent. An understanding of the role of platelets in atrial fibrillation may contribute to the development of new or combination antiplatelet agents that may provide a viable alternative to warfarin for thromboprophylaxis in atrial fibrillation.
Important insights into the pathophysiology of thrombus formation (thrombogenesis) in atrial fibrillation can be made by reference to the different components of Virchow's triad for thrombogenesis, that is, abnormal blood flow, abnormal blood constituents and vessel wall abnormalities. Various studies have confirmed that atrial fibrillation confers a hypercoagulable state, with abnormalities of haemostasis and endothelial function in this condition, that can be altered by introducing antithrombotic therapy and cardioversion from atrial fibrillation to sinus rhythm [1] . The hypercoagulable state in atrial fibrillation is also additive to the presence of structural and flow abnormalities in these patients, such as heart failure or valvular heart disease, thus fulfilling Virchow's triad and substantially increasing the risk of stroke and thromboembolism.
There have been many studies which have focused on clinical risk factors and structural heart disease as risk factors for thrombogenesis in atrial fibrillation. However, the studies exploring the presence of a hypercoagulable state in atrial fibrillation [1, 2] have concentrated on various clotting factors, and markers of endothelial damage or dysfunction, rather than on platelets per se. Thus, a comprehensive understanding of the role of platelet function as a key contributor towards thrombogenesis and the hypercoagulable state in atrial fibrillation has been relatively neglected. The aim of this review is to provide an overview of the pathophysiology of thrombogenesis in atrial fibrillation, with particular reference to platelets, and to summarize present and future antiplatelet therapeutic options for atrial fibrillation.
A brief overview of platelet pathophysiology
Platelets have an important role in the normal haemostatic response. The study of thrombogenesis, including platelet activation, is probably needed to understand the pathophysiological mechanisms underlying cardiovascular disorders and stroke -for example, the interaction of activated platelets and the endothelium may be a particularly important pathway in thrombogenesis. Antiplatelet drugs modify platelet aggregation by interfering with one or more of the various pathways implied in the process of aggregation. Platelet adhesion and a change in shape are the initial physiological responses to platelet stimulation. Once platelet aggregates are formed, there is a tendency for the fibrin threads to be laid on them to form a thrombus. Indeed, the platelet has receptors which bind to various adhesive agents, aggregating agents, inhibitors and procoagulant factors [3] [4] [5] [6] [7] . Platelet activation leads to the transformation of specific proteins (Glycoprotein IIb/ IIIa complexes) into a form that binds fibrinogen [3, 4, 8] .
A simple categorization of various platelet responses includes the 'reversible' platelet responses, which include adhesion, shape change and reversible aggregation [9] , and the 'irreversible' platelet responses that comprise the release reaction and secondary irreversible aggregation [10] , although in reality the process is far more complex.
Indeed, platelet activation has been implicated in the pathogenesis of a diverse spectrum of diseases, which include atherosclerosis [11, 12] , coronary disease [13] and cerebrovascular disease [14] . Furthermore, abnormal platelet function has been associated with atrial fibrillation [15] , cancer, peripheral vascular disease, Alzheimer's disease [16] , inflammatory bowel disorders [17] and recent deep vein thrombosis [18] . Platelet activation also seems to be influenced by diabetes mellitus [19] , smoking [20] , hypertension and also the use of oral contraceptive agents [21] . Nevertheless some artifacts may have confounded the reported studies, such as intervention-related platelet activation.
In general, the quantification of platelet abnormalities can be performed using a wide variety of measures, such as platelet volume, aggregometry [22] , excretion of metabolites [23] , flow cytometry [24] to detect various platelet antigens, and by the measurement of increased plasma levels of platelet products, such as platelet factor 4, beta thromboglobulin [25, 26] and the soluble adhesion molecule P-selectin [27] ( Table 1) . However, some measures (such as platelet volume) are less useful or practical. Furthermore, the choice of method may depend on the nature of the study. For example, measurement of large numbers, say, in epidemiological studies may require the use of plasma markers rather than the more specialized, time-consuming techniques such as flow-cytometry. (Table 2) Platelets appear to play a significant role in a variety of cardiovascular or thromboembolic disorders. It is therefore not surprising that platelets have been found to be implicated in the pathophysiology of thromboembolism in atrial fibrillation.
Platelets in atrial fibrillation

Valvular atrial fibrillation
The association of atrial fibrillation and valvular heart disease results in a substantial stroke and thromboembolic risk, with a 17-fold greater risk than unaffected controls [28] . This increase in thrombogenic risk with valvular heart disease could in part by explained by activation of platelets and the coagulation system.
Mitral stenosis
Platelet activation appears to play an important role in the initial step of thrombus formation in patients with rheumatic mitral stenosis [29] . For example, co-existing mitral stenosis and atrial fibrillation increases the risk of embolism from 3 to 7 times that of solitary mitral stenosis [30] . Indeed, 16% of 622 patients with mitral stenosis and atrial fibrillation had left atrial thrombi identified by echocardiography, compared to only 1% of 192 patients with mitral stenosis in sinus rhythm [31] . In addition to platelet activation, there is also evidence that increased destruction of platelets, as indicated by plasma levels of glycocalicin, a proteolytic fragment of platelet membrane glycoprotein Ib, occurs in patients with rheumatic mitral stenosis [32] ; however, it is also possible that the increased glycocalicin levels could reflect increased platelet mass rather than turnover.
Correction of mitral stenosis by performing balloon mitral valvuloplasty not only confers significant beneficial haemodynamic effects but also seems to affect platelet activation. For example, Kataoka et al. [33] demonstrated that patients with an effective mitral valve orifice area of 2 cm 2 after mitral valvuloplasty had significantly less platelet activation when compared to patients with a mitral valve area <2 cm 2 , at 2-3 months. Moreover, no favourable haemostatic changes were observed in patients with a mitral valve area that widened <0·5 cm 2 following mitral valvuloplasty. By contrast, Goldsmith et al. [34] reported that mean soluble P-selectin levels significantly increased immediately and at 24 h following balloon mitral valvuloplasty in patients with atrial fibrillation, which was associated with increased von Willebrand factor levels (an index of endothelial damage or dysfunction) at 24 h after the procedure, which is in keeping with an increase in platelet activation and endothelial damage/dysfunction following balloon mitral valvuloplasty. These changes may contribute to the increased risk of thromboembolism following the procedure and suggest the need for adequate antiplatelet therapy and anticoagulant therapy following balloon mitral valvuloplasty.
The mitral valve area (and thus, the severity of mitral valve stenosis) is an independent predictor of spontaneous echo contrast in the left atrium [29] . Importantly, the presence of left atrial spontaneous echo contrast indicates stasis within the left atrium, and has been closely associated with haemostatic abnormalities, stroke and thromboembolism. The absolute and relative increase in mitral valve area following percutaneous mitral valvuloplasty also appears to be a significant predictor of resolution of spontaneous echo contrast [36] . These studies therefore suggest that the degree of platelet activation corresponds inversely with the mitral valve orifice area and the more severe the mitral stenosis, the greater is the degree of platelet activation. Furthermore, Kunishima et al. [32] Rheumatic heart disease Platelet aggregation (ohms) (in response to ADP): (mean SD) v Rheumatic heart disease: 14·9 6·4 v Healthy controls: 11·1 4·7 P<0·01 Furui et al. [52] Patients with AF undergoing treadmill exercise.
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Mitral valve prolapse
Mitral valve prolapse has been linked with systemic thromboembolism, especially in young women [37] , and transient ischaemic attacks or partial strokes occurring as a complication of mitral valve prolapse accounted for 40% of these cases in patients aged under 45 years. Mechanisms for this appear to be related to clot or platelet aggregates originating from the rough surface of prolapsed mitral valves or from the traumatized adjacent left atrial surface [38] . Indeed, thrombi have been found on the leaflets of patients with mitral valve prolapse who died of cerebral embolism [39] . There are also reports of shortened platelet survival and increased platelet coagulant activity in patients with cerebral embolism and mitral valve prolapse [39] . Nevertheless, some studies on the platelets have failed to demonstrate an association of platelet activation with pure mitral valve prolapse alone [40] , suggesting that if the predisposition of mitral valve prolapse to thromboembolism were true, it may well operate via a mechanism other than platelet activation alone. Perhaps the severity of mitral regurgitation in mitral valve prolapse may be a factor.
Mitral regurgitation
Mitral regurgitation appears to have variable effects on platelet activation and the risk of thromboembolism, which is dependent on the underlying status of the mitral valve and whether or not there is coexisting atrial fibrillation. Some studies have shown an increase in platelet activation in patients with severe mitral regurgitation [40] in association with mitral valve prolapse, when compared to patients with mitral valve prolapse and mild to moderate mitral regurgitation, which was independent of age and left atrial size. However, other studies failed to demonstrate the same effect [41] , but instead report increased activation of the coagulation system and thrombin generation in these patients.
For example, Karatasakis et al. [42] showed that significant mitral regurgitation correlates with a lower incidence of spontaneous echo contrast, thrombi and embolization in patients with rheumatic mitral valve disease. Similar studies by Hwang et al. [43] and Movsowitz et al. confirmed similar findings [44] . In patients with non-valvular atrial fibrillation, moderate to severe mitral regurgitation seems to protect against stroke especially in patients with left atrial enlargement [45] . Furthermore, the presence of mitral regurgitation appears to reduce intracardiac thrombus in patients with dilated cardiomyopathy [46] . Nevertheless there are limited data relating these clinical observations to the degree of platelet activation or thrombogenesis. However, Goldsmith et al. [47] recently reported an intraoperative study of patients with severe mitral regurgitation, where soluble P-selectin levels (as an index of platelet activation) were significantly lower within the left atrium compared to peripheral vein levels, indicating reduced platelet activation in association with the 'stirring' effect of the (severe) mitral regurgitation jet [47] .
Aortic valve disease
The influence of aortic valve disease differs from that of mitral valve disease on platelet activation. Although thromboembolic events can be associated with aortic stenosis, as evident by the multiple case reports [48] , the mechanisms of thrombogenesis in these patients may be quite different from that of (say) atrial fibrillation. For example, fibrin-platelet deposits (demonstrated on disrupted valvular endothelium), and calcific emboli from calcific aortic stenosis may contribute to the embolism associated with aortic stenosis, with or without the presence of atrial fibrillation.
Goldsmith et al. [49] recently reported that patients with aortic valve disease had higher mean plasma fibrinogen, von Willebrand factor and soluble P-selectin levels, which were not significantly different between patients with aortic stenosis or regurgitation. In mitral stenosis, platelet activation appeared to be more apparent in the pulmonary arterial system than in systemic blood at rest, whilst following exercise, there was a greater increase in platelet activation in systemic arterial blood compared to the pulmonary arterial system [50] . Thus, there may perhaps be some mechanism(s) that increase platelet activation in patients with valve disease and atrial fibrillation, who exercise, which (in patients with mitral stenosis, at least) probably originate within the lung or the left atrium.
Non-valvular atrial fibrillation
Whilst abnormalities of clotting markers are well recognised in non-valvular atrial fibrillation, abnormal platelet activation has also been reported in these patients [1, 50] . However, the exact mechanisms leading to platelet activation in non-valvular atrial fibrillation are uncertain.
A recent study by Minamino et al. [51] suggests that atrial fibrillation is associated with low plasma levels of nitric oxide and this further decreases cyclic guanosine monophosphate (C-GMP) levels within the platelet, resulting in an increase in platelet activation. The same workers previously observed low plasma adenosine levels in patients with atrial fibrillation in comparison to patients without atrial fibrillation [15] , providing a further mechanism for abnormal platelet activation in atrial fibrillation.
The heart rate does not seem to be related to the extent of platelet activation in atrial fibrillation [50] . Therefore, heart rate control therapy itself is unlikely to offer significant benefit in terms of reducing thromboembolic risk in atrial fibrillation. Nevertheless, exercise may increase platelet activation in atrial fibrillation [52] . For example, Furui et al. [52] report an increase in platelet sensitivity to ADP aggregation and the level of beta thromboglobulin in the plasma in 20 patients with lone atrial fibrillation in comparison with age-matched controls when exercising at up to 85% of predicted maximal heart rate. However, Li Saw Hee et al. [53] did not demonstrate any significant increase in soluble P-selectin levels amongst patients with atrial fibrillation exercised to exhaustion [53] . One reason for the difference in findings between the studies by Furui et al. [52] and Li Saw Hee et al. [53] may be the choice of markers of platelet activation, and hence, different pathophysiological release mechanisms. Furthermore, there does not appear to be any significant diurnal variation in abnormal platelet activation in atrial fibrillation, as reflected by changes in soluble P-selectin levels [54] , but this may simply reflect the high thrombogenic state associated with chronic atrial fibrillation.
The extent of platelet activation in non-valvular atrial fibrillation may be related to the other features of the left atrium. For example, an enlarged left atrium and reduced left atrial appendage flow velocity has been correlated with increased platelet activation [55] . The study by Shinohara et al. [55] reported a significant difference in platelet activation amongst patients with nonvalvular atrial fibrillation with a low left atrial appendage velocity (<40 cm . s 1 ) when compared to patients with a high left atrial appendage velocity d40 cm . s 1 [55] . The patients with a low atrial appendage velocity also had a significantly higher prevalence of spontaneous echo contrast and left atrial thrombus, suggesting a relationship between platelet activation and pre-embolic events if atrial fibrillation was accompanied by abnormal flow dynamics within the left atrium. Using scanning electron microscopy, we have recently demonstrated atrial endocardial cell damage, which was most commonly seen in the left atrial appendage amongst patients with mitral valve disease and atrial fibrillation [56] . The interaction between activated platelets or clotting factors and the damaged endocardium may in part contribute to thrombogenesis within the left atrium.
Whether the peripheral venous levels of markers of platelet activation and thrombogenesis truly and wholly reflect left atrial levels of coagulation and platelet activation in non-valvular atrial fibrillation is not exactly clear. Li Saw Hee et al. [57] demonstrated that there was no significant difference in the markers of platelet activation and thrombogenesis between the atria and the periphery vein amongst patients with atrial fibrillation due to mitral stenosis [57] . Peverill et al. [58] found that the markers of coagulation activity in similar patients were no different between the left atrium and the periphery in the absence of left atrial spontaneous echo contrast. However, levels were significantly raised in the left atrium when compared to the periphery in the presence of left atrial spontaneous echo contrast, irrespective of the underlying rhythm. Similarly, Yamamoto et al. [59] demonstrated a significant difference in the levels of some markers of coagulation between the left atrium and the periphery, namely, thrombin-antithrombin III complex and fibrinopeptide A in patients with mitral stenosis, but failed to demonstrate the same with respect to another marker of platelet activation, namely, beta-thromboglobulin [59] .
Platelet activation and thromboembolic risk in atrial fibrillation
Perhaps a continuum exists between normal platelet function, 'statistically' abnormal platelet function and overt thrombosis in patients with cardiovascular disease and stroke. Thus the abnormal platelet activation in atrial fibrillation, as summarized in the evidence above, may represent a 'pre-embolic' status in non-valvular atrial fibrillation [60] . Indeed, platelet activation seems to occur even before the occurrence of spontaneous echo contrast in patients with atrial fibrillation [61] and is correlated with both spontaneous echo contrast [60] and left atrial thrombus [61] in atrial fibrillation. For example, Pongratz et al. [60] demonstrated that the amount of circulating platelets expressing P-selectin was significantly higher in the patients with spontaneous echo contrast or left atrial thrombus in comparison with patients without either of these, or healthy controls. The study by Heppell et al. [61] reported that plasma levels of beta thromboglobulin were independently associated with left atrial thrombus whether or not spontaneous echo contrast was present. Studies in canine models have also demonstrated that platelet activation is significantly associated with silent cerebral infarction in atrial fibrillation [62] . However, other clinical studies have demonstrated platelet activation in atrial fibrillation but failed to relate the former to the risk of thromboembolism. Thus, even though platelet activation appears to be significantly correlated with spontaneous echo contrast and left atrial thrombus, it does not seem to be convincingly correlated with stroke (or transient ischaemic attack) in nonvalvular atrial fibrillation. For example, the study by Gustafsson et al. [63] showed that patients with atrial fibrillation and stroke had no greater platelet activation than patients with atrial fibrillation without stroke, whilst patients with sinus rhythm and stroke had no greater platelet activation than controls in sinus rhythm without stroke; patients with non-valvular atrial fibrillation without stroke had significantly more platelet activation than individuals with stroke in sinus rhythm. Whether platelet activation contributes to stroke/ transient ischaemic attack in atrial fibrillation is not clear, and whether it can be used as a predictor of risk of stroke in atrial fibrillation in addition to other parameters, such as hypertension and left ventricular dysfunction still needs to be clarified.
Thus, the available evidence suggests that thromboembolism in atrial fibrillation is probably due to
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enhancement of various components of the coagulation system due to stasis of blood in the inordinate and irregular atria, rather than to platelet activation per se [64] . The observation of only a minor beneficial effect of antiplatelet therapy in reducing thromboembolic risk in non-valvular atrial fibrillation does not appear unduly surprising. This is in marked contrast to warfarin, which seems to confer significant protection in reducing thromboembolism in atrial fibrillation by (mainly) acting on the coagulation system.
Other unanswered questions also arise. For example, is it the atrial fibrillation or the underlying disease causing atrial fibrillation that activates the platelets and the coagulation system? The available evidence that atrial fibrillation itself activates the platelets is conflicting [65] . For example, studies have shown that in patients with paroxysmal atrial fibrillation, platelet activation takes up to 12 h to be initiated. The study by Sohara et al. [66] reported that the levels of beta thromboglobulin, platelet factor 4 and markers of coagulation were significantly higher at 12 h after the onset of atrial fibrillation in patients with paroxysmal atrial fibrillation when compared to the levels 7 days into the sinus rhythm. The initial 12 h after the onset of the paroxysm of atrial fibrillation may therefore represent a 'safe window' period, during which cardioversion of recent atrial fibrillation in patients with paroxysmal atrial fibrillation may have a low risk of thromboembolism.
Antiplatelet therapy in atrial fibrillation
The most recent meta-analysis of the clinical use of antithrombotic therapy for stroke prevention in atrial fibrillation suggests that aspirin reduces stroke by 22% (95% CI 2% to 38%), whereas warfarin in conventional doses to maintain the INR (International Normalised Ratio) between 2 and 3 reduces stroke by 62% (95% CI, 48% to 72%) [67] . This meta-analysis was based on six trials comparing adjusted dose warfarin with placebo in non-valvular atrial fibrillation, as well as six trials comparing aspirin to placebo in non-valvular atrial fibrillation and five trials comparing warfarin to aspirin (Table 3 ). Other trials have also shown that a combination of aspirin and low or fixed dose warfarin was not beneficial in non-valvular atrial fibrillation when compared to conventional adjusted dose warfarin for thromboprophylaxis in atrial fibrillation [68] . In addition to these clinical trials, one recent trial using markers of thrombogenesis and platelet activation as end-points, found that warfarin (INR 2-3), but not fixed minidose warfarin 1 mg or aspirin 300 mg, significantly reduced beta-thromboglobulin and fibrin D-dimer in non-valvular atrial fibrillation [69] . The AFA-SAK (Copenhagen Atrial Fibrillation, Aspirin and Anticoagulation Study)-2 substudy reported that after 3 months of therapy, only dose-adjusted warfarin (INR 2·0-3·0) had a marked effect on levels of F1+2, an index of thrombogenesis, whilst therapy with fixed minidose warfarin, combined minidose warfarin-aspirin and aspirin alone did not significantly alter F1+2 levels [70] . Similarly, fixed low-dose warfarin 2 mg or an aspirinwarfarin combination therapy did not significantly reduce soluble P-selectin or markers of thrombogenesis in atrial fibrillation patients, whereas conventional adjusted-dose warfarin (INR of 2·0 to 3·0) did so [71] . These observations are therefore consistent with the beneficial effect of full dose warfarin in preventing stroke and thromboembolism in atrial fibrillation and suggest that ultra low dose warfarin, aspirin-warfarin combinations and aspirin may not exert similar beneficial effects.
Whilst the clinical trials have been criticized for their applicability to routine clinical practice, as they were essentially trials of 'packages of care', which included careful follow-up and monitoring, they remain the best available published evidence for the relative efficacy of warfarin and aspirin as thromboprophylaxis in atrial fibrillation. Apart from the risk of bleeding, warfarin also confers the inconvenience of regular anticoagulation monitoring and the benefits of aspirin are inconsistent. Thus, we need the development of new antithrombotic strategies that may provide a viable alternative to warfarin for thromboprophylaxis in atrial fibrillation.
However, the role of other antiplatelet agents in atrial fibrillation remains to be precisely defined. For example, the SIFA (Studio Italiano Fibrillazione Atriale) study used indobufen, a new cycloxygenase inhibiting antiplatelet agent in a comparison with warfarin in patients with non-valvular atrial fibrillation in a secondary prevention trial; although both warfarin and indobufen arms had similar events rates, the risk of haemorrhage was much lower in the indobufen group [72] . The 2nd European Stroke Prevention Study (ESPS-2) used dipyridamole in combination with aspirin for secondary prevention in non-valvular atrial fibrillation. Whereas aspirin only achieved an 8% relative risk reduction of stroke in comparison with dipyridamole, the combination of aspirin and dipyridamole in comparison with aspirin alone and dipyridamole alone resulted in a relative risk reduction of 20% and 27% respectively [73] . Indeed, a retrospective post hoc subgroup analysis of the patients in ESPS-2 who had atrial fibrillation suggested a non-significant trend towards a beneficial effect in stroke prevention from using the aspirin-dipyridamole combination. However, some caution may be necessary, as ESPS-2 used only a low dose of aspirin and the clinical effect was less than expected -thus, the interaction with dipyridamole may have been exaggerated.
Thus, a combination of antiplatelet agents with different mechanisms of action may be superior to aspirin alone in secondary prevention in atrial fibrillation. Indeed, a combination of aspirin and either ticlopidine or clopidogrel appears to be superior to warfarin in preventing coronary stent thrombosis [74, 75] but whether this benefit translates into clinical benefit in conditions such as atrial fibrillation needs to be demonstrated. As Review 2239 yet, there are only limited data on the role for ticlopidine or clopidogrel in atrial fibrillation per se, although a clinical trial comparing clopidogrel, perhaps in combination with aspirin (as in the coronary stent trials), with warfarin in atrial fibrillation would be of great interest. Another advance in antiplatelet therapy is the glycoprotein IIb/IIIa class of drugs, but trials to date have concentrated on acute coronary syndromes where intravenous preparations (such as abciximab) have been very successful in preventing cardiovascular events. However, the oral agents in this class of drugs, which would be required for the treatment of chronic conditions such as atrial fibrillation, have been very disappointing in clinical trials [76] . Until further evidence from antiplatelet strategies is available, current risk stratification strategies [68] suggest that aspirin is best for low risk patients with atrial fibrillation, which generally includes those aged <65 years with no clinical risk factors or structural heart disease. Most risk stratification can be performed on clinical grounds, with some refinement from echocardiography, in order that the highest risk patients with atrial fibrillation can be identified for anticoagulation [68] .
Conclusions
Our understanding of platelet pathophysiology has substantially increased, with a greater appreciation of its role in cardiovascular disorders. Nevertheless, the role of platelets and antiplatelet therapy raises some additional questions. For example, does aspirin reduce stroke in atrial fibrillation by a mechanism other than a reduction in platelet activation? Does platelet activation contribute towards stroke in atrial fibrillation or is it just an associated factor? Does a reduction in platelet activation beneficially influence thromboembolic risk in atrial fibrillation? Furthermore, does a combination of antiplatelet drugs, which act by different mechanisms, have a greater effect on platelet activation? Does a combination of different antiplatelet agents have a comparable effect to warfarin in patients with atrial fibrillation? Only time will provide answers to these questions. S.K. is supported by a non-promotional research fellowship from Sanofi-Winthrop. We acknowledge the support of the City Hospital Research and Development programme for the Haemostasis Thrombosis and Vascular Biology Unit.
